Pasar al contenido principal

ENFERMEDADES CRONICAS Y PROTEOMA FANTASMA: IDENTIFICACION Y VALIDACION DE PROTEINAS ALTERNATIVAS COMO MARCADORES ESPECIFICOS

PID2022-140307OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Contributing to the management of viral infections through simple immunosensing of the arachidonic acid serum level

  • Torrente Rodríguez, Rebeca Magnolia
  • Ruiz Valdepeñas Montiel, Víctor
  • Iftimie, Simona
  • Montero Calle, Ana
  • Pingarrón Carrazón, José Manuel
  • Castro, Antoni
  • Camps, Jordi
  • Barderas Manchado, Rodrigo
  • Campuzano Ruiz, Susana
  • Joven, Jorge
A trendsetting direct competitive-based biosensing tool has been developed and implemented for the determination of the polyunsaturated fatty acid arachidonic acid (ARA), a highly significant biological regulator with decisive roles in viral infections. The designed methodology involves a competitive reaction between the target endogenous ARA and a biotin-ARA competitor for the recognition sites of anti-ARA antibodies covalently attached to the surface of carboxylic acid-coated magnetic microbeads (HOOC-MμBs), followed by the enzymatic label of the biotin-ARA residues with streptavidin-horseradish peroxidase (Strep-HRP) conjugate. The resulting bioconjugates were magnetically trapped onto the sensing surface of disposable screen-printed carbon transducers (SPCEs) to monitor the extent of the biorecognition reaction through amperometry. The operational functioning of the exhaustively optimized and characterized immunosensing bioplatform was highly convenient for the quantitative determination of ARA in serum samples from severe acute respiratory syndrome coronavirus 2 (SARSCoV-2-) and respiratory syncytial virus (RSV)-infected individuals in a rapid, affordable, trustful, and sensitive manner.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Gold-silica hybrid nanolabels decorated with recognition and signaling bioreagents for enhanced electrochemical immunodetection of chemokine ligand-12 in colorectal cancer early diagnosis and monitoring

  • Cabrero Martín, Andrea
  • Santiago, Sara
  • Serafín González-Carrato, Verónica
  • Montero Calle, Ana
  • Pingarrón Carrazón, José Manuel
  • Barderas Manchado, Rodrigo
  • Campuzano Ruiz, Susana
The use of gold–silica nanoconjugates (Au@SiO₂NCs) decorated with biotinylated detection antibodies (b-dAb) and horseradish peroxidase (HRP) is reported for the improved electrochemical immunosensing of chemokine ligand-12 (CXCL12), a relevant chemokine implicated in colorectal cancer (CRC) progression. Implemented on an amperometric sandwich immunoplatform the resulting nanobioconjugates provided significant signal amplification which is attributed to the high enzyme loading capacity and improved antibody orientation. The role played by each of the nanomaterials forming the nanohybrid was evaluated. Under optimized conditions, the developed immunoplatform exhibited a linear response ranging from 72 to 1000 pg mL−1, a 4 times higher sensitivity than the conventional labeling-based immunoplatform, a LOD of 22 pg mL−1, and a storage stability of 1 month. The immunoplatform was applied to the determination of CXCL12 in plasma from healthy individuals and CRC patients. The clinically relevant results obtained demonstrate the potential of plasma CXCL12 levels as a biomarker for both the early diagnosis of CRC and the monitoring of its progression.
Repisalud
Publicación Artículo científico (JournalArticle)

Determining and characterizing circulating nucleosomes in advanced cancer with electrochemical biosensors assisted by magnetic supports and proteomic technologies.

  • Tejerina-Miranda, Sandra
  • Carral-Ibarra, Elisa
  • Gamella, Maria
  • Montero-Calle, Ana Maria
  • Pedrero, María
  • Pingarrón, José M
  • Barderas Manchado, Rodrigo
  • Campuzano, Susana
Measuring and monitoring plasma nucleosomes (small fragments of chromosomes released into the blood during cell death), and their proteomic profiles is a promising approach for improved early detection, diagnosis, and prognosis of cancer diseases as well as for disease and therapy follow-up, contributing to more personalized and effective cancer care. Early detection is imperative in colorectal cancer (CRC), as it has been proven to significantly improve patient outcomes. Indeed, in CRC, blood circulating nucleosome levels and their histone alterations have been correlated with tumor stage and the presence of metastasis. Moreover, they constitute promising markers for CRC monitoring and prognosis in a minimally invasive way. The current technologies used for their detection suffer from notable drawbacks such as non-selective identification and quantification of unknown cancer-relevant proteomic trademarks, expensive procedures, and variable results related to staff experience. Taking advantage of the sensitive, fast, cost-effective, and reliable methodologies that electroanalytical technologies offer for the determination of multilevel biomarkers in liquid biopsies, we report in this paper the first electrochemical immunoplatform for the isolation and determination of circulating nucleosomes in plasma using an anti-H3.1 histone variant, integrated with proteomics insights to confirm nucleosomes isolation and identify associated proteins with potential as CRC biomarkers. The developed bioplatform was used to analyze 0.5 μg of nuclear extracts from CRC cells with different metastatic potential as well as 1/5 diluted plasma samples, demonstrating the suitability to effectively discriminate CRC patients in advanced stages from healthy individuals through liquid biopsy.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comprehensive profiling of Aβ40 and Aβ42 fibril-interacting proteins reveals PRKCG as a drug-targetable regulator of amyloidogenesis in Alzheimer's disease

  • Montero-Calle, Ana
  • Coronel, Raquel
  • Manosalva, Juliana
  • Megías, Diego
  • Ríos, Vivian de los
  • Rábano, Alberto
  • Peláez-García, Alberto
  • Martínez-Useros, Javier
  • Fernández-Aceñero, María Jesús
  • Liste, Isabel
  • Barderas, Rodrigo
Proteins interacting with amyloid beta (Aβ) fibrils could be key to plaque formation in Alzheimer's disease (AD) and represent potential biomarkers and therapeutic targets. Previous proteomic studies using microdissected plaques might have captured non-specific components rather than true Aβ interactors., We gratefully acknowledge the invaluable technical support provided by the Unidad de Microscopía Electrónica of the Instituto de Salud Carlos III. We acknowledge the financial support of the PMP22/00084 grant of the 2022 personalized medicine call from the Instituto de Salud Carlos III (ISCIII), the PI17CIII/00045 grant from the AES-ISCIII program, and grant PID2022-140307OB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” to R.B.; R.C. and I.L. acknowledge grant PID2021-126715OB-I00 financed by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” and PI22CIII/00055 funded by the AES-ISCIII program from ISCIII. A.M.-C. was supported by a predoctoral contract of the Fundación Tatiana Pérez de Guzmán El Bueno, followed by a FPU predoctoral supported by the Spanish Ministerio de Educación, Cultura y Deporte and a postdoctoral grant associated with the PMP22/00084 project of ISCIII., Peer reviewed